130 related articles for article (PubMed ID: 10882330)
1. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
Goto Y; Sekine I; Tanioka M; Shibata T; Tanai C; Asahina H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kikkawa H; Ohki E; Tamura T
Invest New Drugs; 2012 Aug; 30(4):1548-56. PubMed ID: 21748299
[TBL] [Abstract][Full Text] [Related]
2. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Gandara DR; Kawaguchi T; Crowley J; Moon J; Furuse K; Kawahara M; Teramukai S; Ohe Y; Kubota K; Williamson SK; Gautschi O; Lenz HJ; McLeod HL; Lara PN; Coltman CA; Fukuoka M; Saijo N; Fukushima M; Mack PC
J Clin Oncol; 2009 Jul; 27(21):3540-6. PubMed ID: 19470925
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.
Dragnev KH; Whyman JD; Hahn CK; Kebbekus PE; Kokko SF; Bhatt SM; Rigas JR
J Thorac Dis; 2018 Sep; 10(9):5531-5537. PubMed ID: 30416803
[TBL] [Abstract][Full Text] [Related]
4. Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient.
Okano Y; Kunishige M; Kondo Y; Kadota N; Morishita A; Naruse K; Machida H; Hatakeyama N; Hino H; Shinohara T; Sakiyama S; Takeuchi E
Thorac Cancer; 2022 Feb; 13(3):510-513. PubMed ID: 34931476
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of adverse drug reactions of chemotherapeutic agents used in advanced non-small cell lung cancer - experience from a rural tertiary care institution in North Eastern India.
Mukherjee M; Gupta AN; Mukherjee S; Ishore K
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S786-S791. PubMed ID: 38384057
[TBL] [Abstract][Full Text] [Related]
6. Quality of Life in elderly patients with cancer.
Di Maio M; Perrone F
Health Qual Life Outcomes; 2003 Sep; 1():44. PubMed ID: 14525617
[TBL] [Abstract][Full Text] [Related]
7. Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells.
Lu Y; He W; Huang X; Xiao X
BMC Cancer; 2024 Jan; 24(1):55. PubMed ID: 38200409
[TBL] [Abstract][Full Text] [Related]
8. PEG2000-PLA-based nanoscale polymeric micelles reduce paclitaxel-related toxicity in beagle dogs.
Lu J; Han B; Zhang B; Zou B; Hu M; Liu H; Zhou C; Qian F; Wang S; Zhang Y; Lou Y; Chu T; Zhou J; Han B; Zhong H
J Control Release; 2023 Oct; 362():197-209. PubMed ID: 37648084
[TBL] [Abstract][Full Text] [Related]
9. In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer.
Bindal P; Widick P; Costa DB; Rangachari D
Transl Cancer Res; 2020 Mar; 9(3):1311-1318. PubMed ID: 35117478
[No Abstract] [Full Text] [Related]
10. Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.
Moumtzi D; Lampaki S; Zarogoulidis P; Porpodis K; Lagoudi K; Hohenforst-Schmidt W; Pataka A; Tsiouda T; Zissimopoulos A; Lazaridis G; Karavasilis V; Timotheadou H; Barbetakis N; Pavlidis P; Kontakiotis T; Zarogoulidis K
Ann Transl Med; 2016 May; 4(9):161. PubMed ID: 27275474
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
15. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-14-S12-17. PubMed ID: 9331113
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
